期刊文献+

RP-HPLC-UV法测定人血浆及痰液中的莫西沙星浓度 被引量:4

Determination of moxifloxacin in human plasma and sputum by RP-HPLC-UV
原文传递
导出
摘要 目的:建立反相高效液相色谱法以测定入血浆及痰液中莫西沙星浓度,用于比较莫西沙星在血浆及支气管分泌物的分布情况。方法:以乙腈沉淀血浆和痰液中的蛋白质,采用YMC C18色谱柱(150mm×4.6mm,5μm),柱温为室温,流动相为乙腈-0.01mol·L^-1磷酸二氢钾(22:78),磷酸二氢钾用磷酸调节pH值至2.70,流速为1.0mL·min~^-1。以乳酸环丙沙星为内标,检测波长为296nm。结果:血浆样品中的莫西沙星在0.0781~10mg·L^-1范围内线性关系良好(r=0.9956,w=1/C^2);预处理回收率为90.45%~91.82%,方法回收率为96.91%~102.00%,日内RSD为1.17%~3.91%,日间RSD为1.84%~3.13%。痰液标本中的莫西沙星在0.1563~20mg·L^-1范围内线性关系良好(r=0.9913,W=1/C^2);预处理回收率88.01%~91.78%,方法回收率85.12%~114.27%,日内RSD为1.70%~5.26%,日间RSD为2.48%~4.56%。结论:本方法快速、灵敏、准确、简便,适用于盐酸莫西沙星的血浆及痰液中的浓度测定。 Objective:To develop a RP-HPLC method for determining the concentration of moxifloxacin in human plasma and sputum. Methods:The protein in plasma and sputum was precipitated by aeetonitrile,and subsequently quantified by a RP-HPLC equipped with a YMC C18 column (150mm×4.6mm,5μm). The samples were assayed at room temperature. The mobile phase consisted of aeetonitrile-0.01 mol·L^-1 potassium dihydrogen phosphate (22: 78, pH of buffer solution was adjusted to 2.70 by phosphoric acid). Flow rate was 1.0 mL·min^-1. The detection wavelength was set at 296 nm. Ciprofloxaein was used as the internal standard. Results:The linearity of calibrated curves of plasma sample was in the range of 0.078 1 -10 mg·L^-1(r=0.9956,w =1/C^2). The pretreatment recovery was 90.45% -91.82%The methodological recovery was 96.91% - 102.00%. The withinday RSDs were in the range of 1.17% -3.91% and inter-day RSDs of 1.84% -3.13%. The linearity of calibrated curves of sputum sample was in the range of 0. 156 3 -20 mg·L^-1(r = 0. 991 3,w = 1/C^2). The pretreatment recovery was 88.01% -91.78%. The methodological recovery was 85. 12% -114.27%. The within-day RSDs were in the range of 1.70% -5.26% and inter-day RSDs of 2.48% -4.56%. Conclusion:The sensitive,accurate and easily manipulated assay offered a satisfactory tool for the pharmaeokineties and relative bioavailability of moxifloxacin in plasma and sputum samples.
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第15期1419-1423,共5页 Chinese Journal of New Drugs
关键词 盐酸莫西沙星 反相高效液相色谱 血药浓度 痰液浓度 moxifloxaein RP-HPLC plasma eoneentration sputum eoneentration
  • 相关文献

参考文献7

  • 1黄艳,曹兆龙.莫西沙星在下呼吸道感染疾病中的应用[J].中国临床药理学杂志,2002,18(6):467-469. 被引量:6
  • 2GRASELA DM,CHRISTOFALO B, KOLLIA GD,et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment [ J ]. Pharmacotherapy,2000,20(6 Pt 2) :S87 - S94.
  • 3CHIEN SC, ROGGE MC, GISCLON LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses[ J]. Antimicrob Agents Chemother, 1997,41 (10) : 2256 - 2260.
  • 4TATAR US. High-performance liquid chromatography assay for moxifloxacin : pharmacokinetics in human plasma [ J ]. J Pharm Biomed Anal,2007,43 ( 1 ) :320 - 324.
  • 5贺德辉,余江平.RP-HPLC法测定人血浆中莫西沙星的浓度[J].中国药房,2007,18(32):2506-2507. 被引量:23
  • 6张吟,陈一农,陈文发.固相萃取-高效液相色谱法测定人血清中莫西沙星浓度[J].中国医院药学杂志,2007,27(4):481-483. 被引量:24
  • 7LEMOINE T, BREILH D, DUCINT D,et al. Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by High-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge [ J ]. J Chromatogr B Biomed Sci Appl, 2000,742 ( 2 ) : 247 - 254.

二级参考文献14

  • 1张翠莲,Charles H.Nightingale,David P.Nicolau.反相HPLC测定培养基中莫西沙星含量的方法学研究[J].中国药学杂志,2004,39(9):699-701. 被引量:11
  • 2张吟,陈一农,陈文发.固相萃取-高效液相色谱法测定人血清中莫西沙星浓度[J].中国医院药学杂志,2007,27(4):481-483. 被引量:24
  • 3Patrick P, Pierre A. Oral moxifloxacin vs high-doseage amoxicillin in the treatment of mild-to-moderate, communityacquired, suspected pneumococcal pneumonia in adults. Chest Vol Jan, 2001;119:185~195.
  • 4Hoeffken G, Meyer HP. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med, 2001;95:553~564.
  • 5Dean H, Timothy B. Short-course(5-day)moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeutic Trent ,2001;19:117~136.
  • 6Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest, 117,2000(Suppl.2): 380S~385S.
  • 7Anthonisen NR, Manfreda J, Warren CPW, et al.: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med,2001 ;106: 192~204.
  • 8Garcia-Rodriguez J A, Trujillano I, Fresnadillo M J, et al. In: Adam D, Finch R, eds. Moxifloxacin in practice. Maxim Medical, Oxford.1999:37~48.
  • 9Boubakar B.Ba,Renaud Etienne,Dominique Ducint,et al.Determination of moxifloxacin in growth media by high-performance liquid chromatography[J].J.Chromatogr.B,2001,754:107-112.
  • 10Karthick V,Michael GB,James T.Stewart.Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry[J].J.Pharm.Biomed.Anal,2002,30:961-968.

共引文献38

同被引文献28

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部